Clinical trials: Hypersensitivity
Eosinophilic Esophagitis, Connective Tissue Disorders
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on you and your eosinophilic esophagitis.
- Trial name
- NCT01808196
- Testing
- Losartan Potassium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Asthma
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
The purpose of this study is to evaluate the dose-response of different doses of CHF 781 Pressurized Metered Dose Inhaler (pMDI) on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/…
- Trial name
- BEAM (NCT03084718)
- Testing
- CHF 718 pMDI, Beclomethasone Dipropionate (BDP)
- Where
- 134 sites in United States
- Volunteers
- 610 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Epilepsy, Non-Epileptic Seizure
Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy
Electroencephalography (EEG) records electric activity of the brain using electrodes placed on the scalp. EEG is an important tool in the diagnostic work-up of patients with epilepsy.
- Trial name
- CIED (NCT03533374)
- Testing
- Electroencephalogram (EEG) and visual evaluation
- Volunteers
- 100 people
- Sponsor
- Sándor Beniczky
Asthma
AZD1419 Ph2a Study
Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma.
- Trial name
- INCONTRO (NCT02898662)
- Testing
- AZD1419
- Where
- 15 sites in Denmark, Hungary and 2 more
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Bronchial Asthma
Treatment of Bronchial Asthma With Borage and Echium Seed Oils
The aim of this trial is to determine the efficacy of a combination of two botanicals oils, borage seed oil and echium seed oil, as a potential treatment for bronchial asthma.
- Trial name
- NCT00806442
- Testing
- Borage Seed Oil and Echium Seed Oil, Corn Oil
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Brigham and Women's Hospital
Atopic Dermatitis
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous…
- Trial name
- NCT02210780
- Testing
- Dupilumab
- Where
- 42 sites in United States
- Volunteers
- 194 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg
The purpose of this study is to estimate the relative potency for bronchoprotective effect of formoterol Novolizer 12 µg (test) compared to formoterol Aerolizer 12 µg (reference).
- Trial name
- NCT01256086
- Testing
- Formatris 24µg, Formatris 12µg, Foradil P 24µg
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Asthma
Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)
The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol…
- Trial name
- NCT00379288
- Testing
- mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID, Fluticasone/Salmeterol 250/50 mcg BID
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Asthma, Communication
A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults
Few interventions to improve asthma management have targeted low-income minority asthmatic adults and even fewer have focused on the real-world practice where care is provided for these patients.
- Trial name
- HAP2 (NCT01972308)
- Testing
- Patient Advocate, Usual Care
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- University of Pennsylvania
Eosinophilic Esophagitis (EoE)
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study.
- Trial name
- NCT03245840
- Testing
- Budesonide oral suspension
- Where
- 45 sites in United States
- Volunteers
- 133 people
- Sponsor
- Shire
Barrett's Esophagus, Eosinophilic Esophagitis
Study to Image the Esophagus Using the OFDI Capsule
The main purpose of this research is to test the feasibility and tolerability of the tethered capsule Optical Frequency Domain Imaging (OFDI)
- Trial name
- NCT02204150
- Testing
- OFDI Capsule
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Asthma
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
Rationale for the current trial is to evaluate the efficacy and safety of three doses (1.25 µg, 2.5 µg and 5.0 µg ex mouthpiece) of tiotropium inhalation solution in patients with moderate persistent asthma who are still…
- Trial name
- NCT01233284
- Testing
- tiotropium bromide 2.5µg once daily, tiotropium bromide high dose once daily, tiotropium bromide 1.25µg once daily
- Where
- 19 sites in Austria, Germany and 1 more
- Volunteers
- 149 people
- Sponsor
- Boehringer Ingelheim
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Dentin Sensitivity
A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management
This study will evaluate the impact of long-term use of a desensitizing toothpaste containing 0.454 percent (%) stannous fluoride (SnF2) on oral health related quality of life (OHrQoL) in a population of self-reported dentin…
- Trial name
- NCT06045026
- Testing
- Stannous fluoride
- Where
- United States
- Volunteers
- 536 people
- Sponsor
- HALEON
Pediatric, Asthma, Acute Exacerbation, Pediatric ICU
Use of High Frequency Chest Compression in Pediatric Status Asthmaticus
Asthma is a disease resulting in mucus hypersecretion and airways obstruction. This causes difficulty breathing. The High Frequency Chest Compressor (HFCC) is a device that has been shown to decrease respiratory complications in…
- Trial name
- NCT00552448
- Testing
- High Frequency Chest Compression VEST
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Texas Tech University Health Sciences Center
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172821
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 125 sites in United States, Brazil and 9 more
- Volunteers
- 1,032 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis, Atopic Hand Eczema
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema.
- Trial name
- ADHAND (NCT05958407)
- Testing
- Tralokinumab
- Where
- 69 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- LEO Pharma
Asthma
Timely Intravenous Magnesium for Asthma in Children
Many children currently being hospitalized with severe asthma could potentially avoid hospitalization and be sent home if their treatment in the emergency department was more effective.
- Trial name
- IMPACT-ED (NCT05166811)
- Testing
- Magnesium Sulfate, Heptahydrate, 0.9% saline
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Utah
Asthma
School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence
The goal of this new translational project is to test the feasibility and effectiveness of implementing school-based directly observed therapy of preventive asthma medications in a real-world setting, using state-of-the-art…
- Trial name
- SB-PACT (NCT01175434)
- Testing
- School-Based Medication Delivery
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- University of Rochester
Lung Cancer
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
The purpose of this study is to determine whether treatment with temozolomide will shrink small cell lung cancer tumors. Temozolomide is an oral chemotherapy drug that is currently used to treat brain cancer and melanoma.
- Trial name
- NCT00740636
- Testing
- Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.